Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EPIRADBIO

Financiado

Cerrado

Combining epidemiology and radiobiology to assess cancer risksin the breast lun...

Combining epidemiology and radiobiology to assess cancer risksin the breast lung thyroid and digestive tract after exposures to ionizing radiation with total doses in the order of 100 mSv or below Recent epidemiological studies suggest that cancer risk after exposures with doses comparable to the dose limits for occupationally exposed workers may be larger than assumed by ICRP in the derivation of these limits. The value of... ver más

31/03/2015

HMGU

10M€

Presupuesto del proyecto: 10M€

Líder del proyecto

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 17 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-03-31 No tenemos la información de la convocatoria

0% 59% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

17 Participantes

HMGU

0.00€ | Lider

STOCKHOLMS UNIVERSITET

N.D. | Participante

UROS

N.D. | Participante

Proyectos interesantes

PROCARDIO

Medical Technol...

Applied Physics

5M€ Cerrado

CEREBRAD

Medical Technol...

Applied Physics

5M€ Cerrado

ARCH

Medical Technol...

Environmental S...

363K€ Cerrado

ANDANTE

Medical Technol...

Applied Physics

4M€ Cerrado

PID2019-110369RB-I00

Medical Technol...

Applied Physics

165K€ Cerrado

HLEG

Medical Technol...

Applied Physics

77K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 10M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Recent epidemiological studies suggest that cancer risk after exposures with doses comparable to the dose limits for occupationally exposed workers may be larger than assumed by ICRP in the derivation of these limits. The value of cancer risk from such exposures and its dependence on tissue, radiation type and individual factors is largely unknown. The innovative approach proposed here combines epidemiology and radiobiology in order to quantify cancer risks after low-dose or low-dose-rate exposures to ionizing radiation. Key factors of radiation induced carcinogenesis such as genomic instability will be measured in cancer tissues and blood samples from members of the following radio-epidemiological cohorts: French Haemangioma Cohort, Mayak Worker Cohort and thyroid cancer cases after the Chernobyl accident. Inter-cellular communication after exposure to low-dose radiation exposure and its influence on apoptosis, cell proliferation, differentiation and genomic instability will be explored with 2D cell cultures and 3D tissue models. This includes research on stem cells, which will be isolated from healthy human breast tissue. The results of the radiobiological studies will be integrated in the development of models of carcinogenesis for evaluation of major epidemiological cohorts: Atomic Bomb Survivors, French-Swedish-Italian Thyroid Cancer Cohort, Mayak Worker Cohort, Swedish Haemangioma Cohort, UkrAm Cohort on thyroid cancer after the Chernobyl accident, and UK National Registry for Radiation Workers. Cancer risk will be determined for the breast, lung, thyroid and the digestive tract after low-dose-rate exposure to low-LET radiation (external gamma radiation and internal radiation from 131I) and to high-LET radiation (alpha-particles from incorporated plutonium). Lifetime cancer risks including individual risk factors will be calculated to establish a new basis for deriving dose limits and estimating cancer risks including those from medical diagnostic exposures.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores